Bli medlem
Bli medlem

Du är här

2016-03-04

LivaNova plc: LivaNova, PLC Announces Appointment of Vice President Investor Relations and Corporate Communications

LONDON, March 03, 2016 (GLOBE NEWSWIRE) -- LivaNova, PLC (NASDAQ:LIVN)
(LSE:LIVN), a global medical technology company and a leader in the treatment
of cardiovascular diseases, today announced that it has appointed Karen M.
King as Vice President, Investor Relations and Corporate Communications.

Ms. King brings more than 25 years of experience in a broad array of
industries to her role at LivaNova. For the last seven years, she was
Corporate Vice President, Investor Relations at Hospira, a leading provider
of injectable drugs and infusion technologies, and a global leader in
biosimilars. At Hospira, Ms. King was responsible for developing and
executing strategies to build relationships with investment analysts and
shareholders as well as to align Hospira's market capitalization with the
intrinsic value of the company.

Previously, Ms. King served as the Vice President of Investor Relations of
Career Education Corporation, one of the largest global providers of private,
for-profit postsecondary education. Prior to Career Education Corporation,
Ms. King worked in various investor relations and financial analyst roles.

"Karen brings a wide variety of experience to LivaNova, including the
development of comprehensive and global strategic investor relations
programs," commented Vivid Sehgal, LivaNova's Chief Financial Officer. "We
are delighted to welcome Karen as a key member of our senior management
team."

Ms. King earned her bachelor's degree in business from Indiana University in
the United States.

About LivaNova

LivaNova PLC, headquartered in London, UK, is a global medical technology
company formed by the merger of Sorin S.p.A, a leader in the treatment of
cardiovascular diseases, and Cyberonics Inc., a medical device company with
core expertise in neuromodulation. LivaNova transforms medical innovation
into meaningful solutions for the benefit of patients, healthcare
professionals, and healthcare systems. The company employs approximately
4,500 employees worldwide. With a presence in more than 100 countries,
LivaNova operates as three business units: Cardiac Rhythm Management, Cardiac
Surgery, and Neuromodulation, with operating headquarters in Clamart
(France), Mirandola (Italy) and Houston (U.S.A.), respectively.

LivaNova is listed on NASDAQ and listed on the Official List of the UK's
Financial Conduct Authority and traded on London Stock Exchange (LSE) under
the ticker symbol "LIVN".

Safe harbor statement

This press release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended and Section 21E of the
Securities Exchange Act of 1934, as amended. These statements can be
identified by the use of forward-looking terminology, including "may,"
"believe," "will," "expect," "anticipate," "estimate," "plan," "intend,"
"forecast," or other similar words. Statements contained in this press
release are based on information presently available to LivaNova and
assumptions that the parties believe to be reasonable. LivaNova is not
assuming any duty to update this information if those facts change or if the
assumptions are no longer believed to be reasonable. Investors are cautioned
that all such statements involve risks and uncertainties, including without
limitation, statements concerning developing novel opportunities in heart
failure, sleep apnea and percutaneous mitral valve, creating new innovative
solutions that benefit patients, healthcare professionals, and healthcare
systems, and building significant shareholder value. Important factors that
may cause actual results to differ include, but are not limited to: risks
that the new businesses will not be integrated successfully or that the
combined companies will not realize estimated cost savings, value of certain
tax assets, synergies and growth, or that such benefits may take longer to
realize than expected; the inability of LivaNova to meet expectations
regarding the timing, completion and accounting and tax treatments; risks
relating to unanticipated costs of integration, including operating costs,
customer loss or business disruption being greater than expected; reductions
in customer spending, a slowdown in customer payments and changes in customer
demand for products and services; unanticipated changes relating to
competitive factors in the industries in which the company operates; the
ability to hire and retain key personnel; the ability to attract new
customers and retain existing customers in the manner anticipated; reliance
on and integration of information technology systems; changes in legislation
or governmental regulations affecting the company; international, national or
local economic, social or political conditions that could adversely affect
the company or its customers; conditions in the credit markets; risks to the
industries in which LivaNova operates that are described in the "Risk
Factors" section of the Annual Reports on Form 10-K, Quarterly Reports on
Form 10-Q and other documents filed from time to time with the SEC by
Cyberonics, Inc. and LivaNova and the analogous section in annual reports and
other documents filed from time to time by Sorin S.p.A. with the Italian
financial market regulator (CONSOB); risks associated with assumptions made
in connection with critical accounting estimates and legal proceedings;
LivaNova's international operations, which are subject to the risks of
currency fluctuations and foreign exchange controls; and the potential of
international unrest, economic downturn or effects of currencies, tax
assessments, tax adjustments, anticipated tax rates, raw material costs or
availability, benefit or retirement plan costs, or other regulatory
compliance costs. The foregoing list of factors is not exhaustive. You
should carefully consider the foregoing factors and the other risks and
uncertainties that affect the parties' businesses, including those described
in Cyberonics' Annual Report on Form 10-K, as amended from time to time,
Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other
documents filed from time to time with the SEC by Cyberonics and LivaNova and
those described in Sorin's annual reports, registration documents and other
documents filed from time to time with CONSOB by Sorin. LivaNova does not
give any assurance (1) that LivaNova will achieve its expectations, or (2)
concerning any result or the timing thereof, in each case, with respect to
any regulatory action, administrative proceedings, government investigations,
litigation, warning letters, consent decree, cost reductions, business
strategies, earnings or revenue trends or future financial results.

For more information, please visit www.livanova.com, or contact:
Investor Relations:

Vivid Sehgal
Chief Financial Officer
e-mail: investor.relations@livanova.com

Investor Relations and Media:
Greg Browne
Senior Vice President, Finance
Phone: +1 (281) 228-7262
Fax: +1 (281) 218-9332
e-mail: corporate.communications@livanova.com

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: LivaNova plc via Globenewswire

HUG#1991358

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.